Bristol Myers Squibb Company
NEWS
This morning, the pharma giant signaled it will fail to meet a deadline related to $9 per share Contingent Value Rights (CVR) tickets, essentially killing that payment.
A recent study shows that Bristol Myers Squibb’s oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib was associated with noticeable improvements in signs and symptoms of psoriatic arthritis compared with placebo.
Here’s a look at some of the upcoming target action dates on the U.S. FDA’s calendar.
Setbacks and delays caused by COVID-19 are making everyone, in every facet of life, nervous. This week, that includes legacy Celgene CVR investors who are staging a mass exodus as two drugs under the agreement near the deadline and one, Liso-cel, faces inspection delays.
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
It’s a busy time of year for the biopharma industry, as most companies have begun reporting third-quarter financials.
“With limited oral therapeutic options available for psoriasis, there remains a significant need for safe and effective therapies,” said April Armstrong, associate dean and professor of dermatology at the University of Southern California.
Through this collaboration, Insitro will utilize its proprietary platform, Insitro Human (ISH), to create induced pluripotent stem cell (iPSC) derived disease models for both diseases.
It was a moderately busy week for clinical trial news. Here’s a look.
JOBS
IN THE PRESS